302440.KS
SK bioscience Co.,Ltd.
KSC · Healthcare · Biotechnology · KR
KRW 37,750.00
+0.80%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 659.3B | 651.4B | 267.5B | 369.5B | 456.7B |
| Cost of Revenue | 592.5B | 591.9B | 236.6B | 227.7B | 217.1B |
| Gross Profit | 66.8B | 59.5B | 31.0B | 141.8B | 239.6B |
| Operating Expenses | |||||
| R&D Expense | 67.5B | 97.7B | 71.4B | 85.7B | 58.0B |
| SG&A Expense | 42.4B | 48.2B | 40.9B | 25.3B | 27.3B |
| General & Admin Expense | 9.6B | 10.7B | 8.7B | 7.0B | 5.6B |
| Selling & Marketing Expense | 32.8B | 37.6B | 32.2B | 18.4B | 21.7B |
| Other Expenses | 143.1B | 64.9B | 57.2B | 43.1B | 39.3B |
| Total Operating Expenses | 235.2B | 210.8B | 169.4B | 146.6B | 124.6B |
| Cost and Expenses | 816.0B | 802.7B | 406.0B | 374.2B | 341.7B |
| Operating Income (EBIT) | (156.7B) | (151.3B) | (138.4B) | (4.7B) | 115.0B |
| Non-Operating | |||||
| Interest Income | 17.5B | 15.7B | 7.0B | 13.6B | 4.9B |
| Interest Expense | 12.7B | 9.4B | 3.7B | 1.4B | 2.5B |
| Net Interest Income | 4.8B | 6.3B | 3.3B | 12.2B | 2.4B |
| Other Non-Op Income/Expense | 49.1B | 65.5B | 49.3B | 12.1B | 26.7B |
| Non-Operating Income (excl Interest) | (38.8B) | — | (53.0B) | (13.5B) | (29.2B) |
| EBT (Pre-Tax Income) | (101.2B) | (85.9B) | (89.1B) | 7.3B | 141.7B |
| Income Tax Expense | (15.6B) | (29.7B) | (39.0B) | (15.0B) | 19.3B |
| Bottom Line | |||||
| Net Income | (79.3B) | (56.2B) | (53.9B) | 22.3B | 122.5B |
| Earnings from Cont. Ops | (85.6B) | (56.2B) | (50.1B) | 22.3B | 122.5B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (83.4B) | (56.2B) | (53.9B) | 22.3B | 122.5B |
| Per Share | |||||
| Basic EPS | (₩1,066) | (₩718) | (₩700) | ₩291 | ₩1,596 |
| Diluted EPS | (₩1,066) | (₩718) | (₩701) | ₩290 | ₩1,590 |
| Revenue Per Share | ₩8,403 | ₩8,329 | ₩3,466 | ₩4,818 | ₩5,953 |
| Shares | |||||
| Basic Shares Outstanding | 78.5M | 78.2M | 77.2M | 76.7M | 76.7M |
| Diluted Shares Outstanding | 78.5M | 78.2M | 77.4M | 77.0M | 77.0M |
| Profitability Metrics | |||||
| EBITDA | (125.6B) | (60.3B) | (36.2B) | 43.5B | 171.4B |
| D&A | 98.2B | 91.0B | 49.2B | 34.8B | 27.2B |
| EBIT | (223.9B) | (151.3B) | (85.4B) | 8.7B | 144.2B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026